Turnover of the gastric H+,K+-Adenosine triphosphatase α subunit and its effect on inhibition of rat gastric acid secretion

doi:10.1016/0016-5085(95)90571-5

Gastroenterology

Volume 109, Issue 4, October 1995, Pages 1134-1141

https://doi.org/10.1016/0016-5085(95)90571-5 Get rights and content

Abstract

$Background & Aims$ : The rate of turnover and the effect of inhibition of acid secretion on the turnover of gastric H⁺,K⁺-adenosine triphosphatase (ATPase) is unknown. The aim of this study was to determine the turnover of the α subunit of gastric H⁺,K⁺-ATPase in rats under control conditions and during inhibition of acid secretion by ranitidine or omeprazole. $Methods$ : The turnover of the α subunit of the ATPase was determined by measuring the loss of incorporated ³⁵S-methionine. This was compared with the rate of recovery of K⁺-stimulated ATPase activity in the omeprazole-treated animals. $Results$ : The half-life of the α subunit was 54 hours. A 1-week treatment with omeprazole had no significant effect, but the half-life increased to 125 hours (P < 0.01) after continuous ranitidine infusion. After omeprazole treatment, K⁺-stimulated ATPase activity recovered with a half-time of 15 hours. $Conclusions$ : The turnover of the gastric ATPase subunit was independent of omeprazole inhibition but was prolonged by ranitidine. The effect of ranitidine suggests that the resting pump in tubulovesicles may turn over more slowly than the stimulated pump in the secretory canaliculus. The rapid recovery of ATPase activity compared with turnover after omeprazole is caused by both H⁺,K⁺-ATPase synthesis and loss of covalently bound drug.

References (40)

DW Burget et al.
Is there an optimal degree of acid suppression for healing of duodenal ulcers?
JG Forte et al.
Unique enzymes of purified microsomes from pig fundic mucosa
Gastroenterology
(1975)
G Sachs et al.
A nonelectrogenic H⁺ pump in plasma membranes of hog stomach
J Biol Chem
(1976)
DR Scott et al.
The site of acid secretion in the mammalian parietal cell
Biochim Biophys Acta
(1993)
B Wallmark et al.
The relationship between gastric acid secretion and gastric H⁺,K⁺-ATPase activity
J Biol Chem
(1985)
P Lorentzon et al.
Inhibition of (H⁺, K⁺)-ATPase by omeprazole in isolated gastric vesicles requires proton transport
Biochim Biophys Acta
(1987)
WB Im et al.
Reversal of antisecretory activity of omeprazole by sulfhydryl compounds in isolated rabbit gastric glands
Biochim Biophys Acta
(1985)
J Fryklund et al.
Specific labeling of gastric H,K ATPase by omeprazole
Biochem Pharmacol
(1988)
HF Helander et al.
Quantitative ultrastructural studies on gastric parietal cells
Gastroenterology
(1972)
H Fujisaki et al.
Inhibitions of acid secretion by E3810 and omeprazole and their reversal by glutathione
Biochem Pharmacol
(1991)

WB Im et al.

Irreversible inactivation of rat gastric (H⁺-K⁺)-ATPase in vivo by omeprazole

Biochem Biophys Res Commun

(1985)

B Ryberg et al.

Gastrin stimulates the self-replication of enterochromaffin-like cells in the rat stomach

Gastroenterology

(1990)

EC Rabon et al.

Radiation inactivation analysis of oligomeric structure of the H,K-ATPase

J Biol Chem

(1988)

OH Lowry et al.

Protein measurement with the Folin phenol reagent

J Biol Chem

(1951)

H Schagger et al.

Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1–100 kDa

Anal Biochem

(1987)

F Mercier et al.

Antibody epitope mapping of the gastric H⁺/K⁺-ATPase

Biochim Biophys Acta

(1993)

D Lebel et al.

A convenient method for ATPase assay

Anal Biochem

(1978)

A Yoda et al.

On the reversibility of binding of cardiotonic steroids to a partially purified Na⁺K⁺ activated adenosine triphosphatase from beef brain

Biochem Biophys Res Commun

(1970)

IM Arias et al.

Studies on the synthesis and degradation of proteins of the endoplasmic reticulum of rat liver

J Biol Chem

(1969)

B Ryberg et al.

Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach

Regul Peptides

(1989)

Cited by (75)

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
2011, Biochemical Pharmacology
TAK-438 is a novel potassium-competitive acid blocker (P-CAB) type antisecretory agent that reversibly inhibits gastric H⁺, K⁺-ATPase. Previously, we showed that TAK-438 has superior efficacy compared to lansoprazole, a proton pump inhibitor, in the inhibition of acid secretion in vivo. In this study, we investigated the differences in the mode of actions of the two drugs using primary cultured rabbit gastric glands. TAK-438 and lansoprazole inhibited gastric acid formation in acutely isolated gastric glands (IC₅₀ values, 0.30 and 0.76 μM, respectively). In cultured gastric glands that were preincubated with TAK-438, the inhibitory effect on forskolin-stimulated acid formation was augmented over the incubation period, whereas the inhibitory effect of lansoprazole was not affected by time of incubation. Next, we evaluated the durations of the actions of TAK-438 and lansoprazole after gastric glands were incubated with either drug for 2 h followed by washout. Even 8 h after the drug washout, TAK-438 at higher concentrations inhibited acid formation, but the inhibitory effect of lansoprazole disappeared immediately after washout. Additionally, only a small amount of [¹⁴C] lansoprazole accumulated in resting glands, and this accumulation was enhanced by treatment with 1 μM of forskolin. In contrast, high levels of [¹⁴C] TAK-438 accumulated in both resting and forskolin-treated glands. Furthermore, a 2-h preincubation followed by washout demonstrated a slow clearance of [¹⁴C] TAK-438 from the glands. These findings suggest that TAK-438 exerts a longer and more potent antisecretory effect than lansoprazole as a result of its high accumulation and slow clearance from the gastric glands.
In search of the grail: A race for acid suppression
2019, Revista de Gastroenterologia de Mexico
Los inhibidores de la bomba de protones (IBP) son el estándar de referencia para el tratamiento de las enfermedades relacionadas con el ácido. En la enfermedad por reflujo gastroesofágico (ERGE) la supresión ácida se asocia con una alta tasa de cicatrización de la mucosa; sin embargo, la respuesta sintomática difiere entre los fenotipos endoscópicos. Las manifestaciones extraesofágicas tienen buena respuesta clínica en quienes presentan una exposición anormal al ácido (prueba diagnóstica) en el esófago.
Los IBP han demostrado su efectividad para disminuir la intensidad sintomática en el reflujo nocturno y en los trastornos del sueño, mejorando la calidad de vida y la productividad laboral. Esto se logra, en ocasiones, mediante las modificaciones al fraccionar o aumentar la dosis, así como la galénica.
Estos fármacos no están exentos de aspectos controversiales en relación con los eventos adversos asociados. El desarrollo tecnológico está encaminado a mejorar el rendimiento del IBP mediante el incremento de la vida media, la concentración máxima y el área bajo la curva de las concentraciones plasmáticas mediante la galénica, y por otra parte a crear fármacos más seguros y tolerables.
En esta revisión nos enfocamos a los mecanismos de acción, las propiedades farmacocinéticas y los avances tecnológicos para incrementar el rendimiento farmacológico de un IBP.
Proton pump inhibitors are the reference standards for the treatment of acid-related diseases. Acid suppression in gastroesophageal reflux disease is associated with a high rate of mucosal cicatrization, but symptom response differs among endoscopic phenotypes. Extraesophageal manifestations have a good clinical response in patients that present with abnormal acid exposure (diagnostic test) in the esophagus.
Proton pump inhibitors have shown their effectiveness for reducing symptom intensity in nighttime reflux and sleep disorders, improving quality of life and work productivity. That can sometimes be achieved through dose modifications by splitting or increasing the dose, or through galenic formulation.
Proton pump inhibitors are not exempt from controversial aspects related to associated adverse events. Technological development is directed at improving proton pump inhibitor performance through increasing the half-life, maximum concentration, and area under the curve of the plasma concentrations through galenic formulation, as well as creating safer and more tolerable drugs.
The present review is focused on the mechanisms of action, pharmacokinetic properties, and technological advances for increasing the pharmacologic performance of a proton pump inhibitor.
Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori
2024, Postgraduate Medicine
Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance
2023, Pharmacological Reviews
Peptic Ulcer Disease
2021, Geriatric Gastroenterology, Second Edition
Proton-pump inhibitors in adults and pediatric patients: Use and abuse
2020, Revista de Chimie

View all citing articles on Scopus

View full text

Turnover of the gastric H+,K+-Adenosine triphosphatase α subunit and its effect on inhibition of rat gastric acid secretion

Abstract

Gastroenterology

J Biol Chem

Biochim Biophys Acta

J Biol Chem

Biochim Biophys Acta

Biochim Biophys Acta

Biochem Pharmacol

Gastroenterology

Biochem Pharmacol

Biochem Biophys Res Commun

Gastroenterology

J Biol Chem

J Biol Chem

Anal Biochem

Biochim Biophys Acta

Anal Biochem

Biochem Biophys Res Commun

J Biol Chem

Regul Peptides

Turnover of the gastric H⁺,K⁺-Adenosine triphosphatase α subunit and its effect on inhibition of rat gastric acid secretion